Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 12/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 7/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16936086 | 0.81 | NTRK1 (0.49) | NTRK1JAK2 | |
| SCHEMBL16946723 | 0.78 | NTRK1 (0.50) | NTRK1JAK2 | |
| SCHEMBL29511265 | 0.78 | NTRK1 (0.49) | NTRK1JAK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL16935988 | 0.78 | NTRK1 (0.49) | NTRK1JAK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL30085905 | 0.78 | NTRK1 (0.49) | NTRK1JAK2 | |
| SCHEMBL16936085 | 0.78 | NTRK1 (0.45) | NTRK1IRAK4JAK2 | |
| SCHEMBL21941661 | 0.78 | JAK2 (0.42) | NTRK1IRAK4JAK2ALDH1A1LMNA | |
| SCHEMBL18352547 | 0.77 | NTRK1 (0.51) | NTRK1JAK2 | |
| SCHEMBL19614122 | 0.77 | NTRK1 (0.49) | NTRK1JAK2 | |
| SCHEMBL16946746 | 0.77 | NTRK1 (0.48) | NTRK1JAK2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3636649-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |